




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 213/38, 213/40, 409/06 C07D 405/06, 401/06, 233/54 C07D 241/12, 241/16	A1	(11) International Publication Number: WO 93/09095 (43) International Publication Date: 13 May 1993 (13.05.93)
(21) International Application Number: PCT/GB92/01971 (22) International Filing Date: 28 October 1992 (28.10.92) (30) Priority data: 785,590 30 October 1991 (30.10.91) US (71) Applicant (for SD only): FISONS PLC [GB/GB]; Fison House, Princes Street, Ipswich, Suffolk IP1 1QH (GB). (71) Applicant (for all designated States except SD US): FISONS CORPORATION [US/US]; 755 Jefferson Road, Rochester, NY 14623 (US). (72) Inventors; and (75) Inventors/Applicants (for US only) : GRIFFITH, Ronald, Conrad [US/US]; 41 Northfield Gate, Pittsford, NY 14534 (US). MURRAY, Robert, John [US/US]; 172 Lackine, Rochester, NY 14618 (US). SCHMIESING, Richard, John [US/US]; 466 Reeves Road, Pittsford, NY 14534 (US).		(74) Agent: WRIGHT, Robert, Gordon, McRae; Fisons plc, 12 Derby Road, Loughborough, Leicestershire LE11 0BB (GB). (81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i>

(54) Title: 2-HETEROCYCLICETHYLAMINE DERIVATIVES AND THEIR USE AS PHARMACEUTICALS

**(57) Abstract**

Compounds of formula (I), wherein A represents C=C, S or O; Q represents a 5- or 6-membered unsaturated heterocyclic ring having a nitrogen atom in the position adjacent to the point of attachment, 0-3 further heteroatoms selected from N, O and S, and substituents R⁶ and R⁷; R¹ represents H or C₁₋₆alkyl; R² represents H, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl, C₃₋₆cycloalkyl or NH₂CH₂CO-; in addition, R¹ and R² taken together may form a C₃₋₅alkylene chain; R³ represents H, C₁₋₆alkyl, C₃₋₆alkenyl, C₃₋₆alkynyl; R⁴ and R⁵ independently represent H, OH, C₁₋₆alkoxy, C₁₋₆alkyl, halogen, trifluoromethyl or NR⁸R⁹; R⁶ and R⁷ independently represent H, OH, C₁₋₆alkoxy, C₁₋₆alkyl, halogen, trifluoromethyl, C₁₋₆hydroxyalkyl, amidino, CONH₂ or NR⁸R⁹; in addition, R⁶ and R⁷ may independently represent O when substituted on N; R⁸ and R⁹ independently represent H or C₁₋₆alkyl; with various provisos; and pharmaceutically acceptable derivatives thereof; are useful as pharmaceuticals, in particular in the treatment of neurological disorders.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

2-Heterocyclicethylamine derivatives and their use as pharmaceuticals

This invention relates to 2-heterocyclicethylamine derivatives, processes for their preparation, pharmaceutical formulations comprising them, and to their use as pharmaceuticals, in particular in the treatment of neurological disorders.

Compounds which possess anticonvulsant or N-methyl-(d)-aspartate (NMDA) blocking properties are useful in the treatment and/or prevention of neurological disorders such as stroke, cerebral ischaemia, cerebral palsy, hypoglycaemia, epilepsy, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia, Parkinson's disease, anoxia and neuronal damage associated with substance abuse, for example, narcotics or cocaine. Undesirable side effects are associated with some neuroprotective agents and compounds with minimal psychotomimetic effects are desirable.


15

Certain 2-heteroarylethylamines and derivatives thereof have been described as pharmaceuticals. For example, European Patent Application No 346791 describes 1,2-diarylethylamines in which the amine group is a cyclic amine as useful for controlling neuropathological processes and the neurodegenerative consequences thereof in mammals. US Patent No 4,769,466 describes N-(2-aminoacetyl)-derivatives of 1,2-diarylethylamines in which one of the aryl groups is pyridine and the other is phenyl as anticonvulsants. European Patent Application No 356035 discloses α -phenyl-2-pyridineethanamine as being useful for the treatment of neurological disorders.

Other 2-heteroarylethylamines and derivatives thereof have been described without mention of pharmaceutical utility. For example US Patent No 4,769,466 describes 1,2-diarylethylamines in which one of the aryl groups is pyridine and the other is phenyl as intermediates. German Patents Nos 2447258 and DE 2415063 disclose 4-methyl, 5-ethyl and 6-methyl- α -phenyl-2-pyridineethanamine, α -(2-furanyl)- and α -(2-thienyl)-2-pyridineethanamine as intermediates to the corresponding amidines. Cliffe *et al*, Synthesis (12), 1138-1140 (1985) describe N-(1,1-dimethylethyl)- α -phenyl-2-pyridineethanamine as an example of a highly hindered sec-alkyl-tert-alkylamine.

Shuman *et al*, J Org Chem 27, 1970-1972 (1962) describe N-[α -(2-pyridinylmethyl)benzyl] acetamide as an intermediate.

According to the invention, there is provided a compound of formula I,



wherein

A represents C=C, S or O;

Q represents a 5- or 6-membered unsaturated heterocyclic ring having a nitrogen atom in the position adjacent to the point of attachment, 0-3 further heteroatoms selected from N, O and S, and substituents R⁶ and R⁷;

R¹ represents H or C₁₋₆ alkyl;

R² represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₆ cycloalkyl or NH₂CH₂CO-;

in addition, R¹ and R² taken together may form a C₃₋₅ alkylene chain;

R³ represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl;

R⁴ and R⁵ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl or NR⁸R⁹;

R⁶ and R⁷ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl, C₁₋₆ hydroxyalkyl, amidino, CONH₂ or NR⁸R⁹;

in addition, R⁶ and R⁷ may independently represent O when substituted on N;

R⁸ and R⁹ independently represent H or C₁₋₆ alkyl;

provided that:

- (1) when A represents C=C; R², R³, R⁴ and R⁵ each represent H; and Q represents 2-pyridinyl, 5- or 6-methyl-2-pyridinyl or 5-ethyl-2-pyridinyl; then R¹ is other than H;
- (2) when A represents C=C; R² represents t-butyl or NH₂CH₂CO-; R³, R⁴ and R⁵ each represent H; and Q represents 2-pyridinyl; then R¹ is other than H;
- (3) when A represents S or O; R² and R³ represent H; and Q represents 2-pyridinyl; then, either R¹ or one of R⁴ and R⁵ is other than H;


and pharmaceutically acceptable derivatives thereof.

Specific heterocyclic rings which Q may represent include non-aromatic rings such as thiazoline, diazoline and oxazoline. However, Q preferably represents an aromatic ring, for example pyridine, pyrazine, pyrimidine, pyridazine, 1,2,4-triazine, imidazole, pyrazole, 2H-pyrrole, isoxazole, isothiazole, oxazole, thiazole, 1,2,4-oxadiazine, 1,2,4-thiadiazine and 1,2,4-triazole.

Alkyl groups which R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 and R^9 may represent include methyl, ethyl, propyl, isopropyl, n-butyl, iso-butyl and s-butyl. Alkoxy groups which R^4 , R^5 , R^6 and R^7 may represent include methoxy, ethoxy and propoxy. Halogen groups which R^4 , R^5 , R^6 and R^7 may represent include fluorine, chlorine, bromine or iodine. Alkenyl groups which R^2 and R^3 may represent include 2-propenyl, 2-butenyl and 2-methyl-2-propenyl. Alkynyl groups which R^2 and R^3 may represent include 2-propynyl and 2-butyryl. Cycloalkyl groups which R^2 and R^3 may represent include cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

Preferably, A represents C=C; Q represents 2-pyridinyl or 2-pyrazinyl; R^1 represents C_{1-6} alkyl (in particular methyl); R^2 is hydrogen, methyl, ethyl, isopropyl or NH_2CH_2CO- ; R^3 is hydrogen; R^4 , R^5 , R^6 and R^7 each represent H.

A preferred group of compounds which may be mentioned is that defined by formula Ia,



30 in which R^{2a} represents H, methyl, ethyl or propyl.

Pharmaceutically acceptable derivatives of the compounds of formula I include pharmaceutically acceptable acid addition salts, quaternary salts and compounds which

will be suitable bioprecursors (prodrugs) to the compounds of formula I. Of particular interest are acid addition salts.

Pharmaceutically acceptable acid addition salts of the compounds of formula I include salts of mineral acids, for example, hydrohalic acids (such as hydrochloric or hydrobromic); or organic acids, for example, formic, acetic or lactic acids.

Quaternary salts of the compounds of formula I include salts of C_{1-6} alkyl halides.

Bioprecursors of the compounds of formula I include urethane derivatives and amino acid amide derivatives of one or more of the amino groups, and when a compound of formula I bears a hydroxyl group, esters of alkanolic and amino acids. Urethane derivatives include C_{1-6} alkoxycarbonyl groups. Amino acid amide and ester derivatives may be formed from α -amino acids.

Certain compounds of formula I are optically active. All optical isomers are included within the scope of the invention.


According to a second aspect of the invention, there is provided a process for the preparation of a compound of formula I, or a pharmaceutically acceptable derivative thereof, which comprises:

(a) preparing a compound of formula I in which R^1 , R^2 and R^3 each represent hydrogen, by reacting a corresponding compound of formula II,




II

wherein Q is as defined in claim 1, with a compound of formula III,



wherein R^4 , R^5 and A are as defined in claim 1, in the presence of a base;


(b) preparing a compound of formula I in which R^2 and R^3 represent hydrogen, by reacting the corresponding azide of formula IV,



in which Q, R^1 , R^4 , R^5 and A are as defined in claim 1, under Curtius reaction conditions;

10

(c) preparing a compound of formula I in which R^2 represents H and R^3 represents C_{1-6} alkyl, by reduction of a corresponding compound of formula IVa,




wherein R^{3a} represents C_{1-6} alkanoyl and Q, R^1 , R^4 and R^5 are as defined in claim 1;

20 (d) preparing a compound of formula I in which one or both of R^2 and R^3 represents methyl, by reacting the corresponding compound of formula I in which one or both of R^2 and R^3 is hydrogen with formaldehyde and formic acid;


(e) preparing a compound of formula I in which R^2 or R^3 represents C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl by reacting the corresponding compound of formula I in which
 25 R^2 or R^3 represents hydrogen with an alkylating agent of the formula R^{10} -M, in which R^{10} represents a C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl group and M represents a suitable leaving group;

(f) preparing a compound of formula I in which R^1 represents H or C_{1-6} alkyl, R^2 represents C_{2-6} alkyl or C_{3-6} cycloalkyl, R^3 represents H and, in addition, R^1 and R^2
 30 taken together may form a $C_{3,5}$ alkylene chain, by reduction of the corresponding imine of formula V,




wherein Q, R¹, R⁴, R⁵ and A are as defined in claim 1, R² represents C₂₋₆ alkylidene or C₃₋₆ cycloalkylidene, and, in addition, R¹ and R² taken together may form a C₃₋₅ alkylidene chain;

(g) preparing a compound of formula I in which R¹, R² and R³ represent hydrogen, by reductive amination of the corresponding ketone of formula VI,



7



wherein L is a suitable leaving group and Q, A, R¹, R³, R⁴ and R⁵ are as defined in claim 1, with ammonia; or

- (j) preparing a compound of formula I by removal of a protecting group from an amino- or hydroxy-protected analogue of a compound of formula I;
and where desired or necessary converting the resulting compound of formula I into a pharmaceutically acceptable derivative thereof or vice versa.

In the reaction of process (a) suitable bases include, for example, butyl lithium or lithium bis(trimethylsilyl)amide, in an aprotic solvent or a mixture of solvents, for example, tetrahydrofuran or hexanes and at a temperature of, for example, from -80°-30°C.

The rearrangement of process (b) may be carried out in an inert solvent, for example, toluene, at a temperature of, for example, from 50°-150°C. Hydrolysis of the corresponding isocyanate formed *in situ* may be accomplished with water to give the corresponding amine or with an alcohol, for example, benzyl alcohol or ethanol, to give the corresponding carbamate.

The reduction of process (c) may be carried out with a hydride reducing agent, for example, diborane or sodium bis(2-methoxyethoxy)aluminum hydride in an aprotic solvent, for example, tetrahydrofuran. The reduction may be carried out at a temperature of, for example, from 0°-100°C.

In the reaction of process (d), methylation is accomplished by heating the amine with formic acid and formaldehyde at a temperature of, for example, from 50°-100°C.

In the reaction of process (e), suitable leaving groups which M may represent include, for example, halogen, preferably chlorine, bromine or iodine, or an alkyl- or aryl-

sulphonate group, for example, mesylate or tosylate. The alkylation reaction may be carried out in an aprotic solvent, for example, acetonitrile, in the presence of a base, for example, potassium carbonate, and at a temperature of, for example, from 0°-100°C.

- 5 The reduction of process (f) may be carried out with a hydride reducing agent, for example, sodium borohydride, in a protic solvent, for example, methanol, and at a temperature of, for example, from 0°-80°C; or the reduction may be carried out in the presence of hydrogen and a hydrogenation catalyst, for example, platinum in a protic solvent such as a lower alkanol, for example, ethanol and at a temperature of, for
10 example, from 0°-50°C.

The reaction of process (g) may be carried out in a protic solvent, for example, a lower alkanol such as methanol, in the presence of a hydride reducing agent, for example, sodium cyanoborohydride, and an ammonium salt, for example, ammonium acetate, and
15 at a temperature of, for example, from 0°-80°C.

The reduction of process (h) may be carried out in the presence of hydrogen and a hydrogenation catalyst, for example, platinum in a protic solvent such as a lower alkanol, for example, ethanol, or an alkanolic acid such as acetic acid, and at a temperature of,
20 for example, from 0°-80°C.

In the reaction of process (i) suitable leaving groups which L may represent include halogen, especially chlorine or bromine. The reaction may be carried out in a protic solvent, for example, ethanol, and at a temperature of, for example, from 0°-100°C.

25


In the reaction of process (j), removal of the protecting group depends on the nature of the protecting group and includes acidic or basic cleavage or hydrogenolysis. Suitable amine protecting groups are, for example, benzyl, ethoxycarbonyl, benzyloxycarbonyl, t-butyloxycarbonyl or C₁₋₆ alkanoyl. One particularly suitable protecting group is
30 benzyloxycarbonyl, which may readily be removed by hydrogenolysis or hydrogen bromide in acetic acid. Other groups that may be mentioned include t-butyloxycarbonyl, (Boc), which is removed by cold trifluoroacetic acid. Further protecting groups and

methods for their removal are described in T W Greene, Protective Groups in Organic Synthesis, Wiley-Interscience, 1981.

It will be appreciated by those skilled in the art that in processes (a)-(i) above certain functional groups in the reactants (for example when R^4 , R^5 , R^6 or R^7 represent OH) are advantageously protected by a suitable protecting group (for example to avoid their transformation by the reaction conditions), which may be removed subsequently as described in process (j).

Functional groups which R^4 , R^5 , R^6 and R^7 may represent may be interconverted, introduced, or derived from appropriate precursors using conventional methods. The reaction conditions of processes (a)-(i) above may also be used to interconvert, derive or introduce such functional groups.


The starting materials for the products of reaction (b), may be obtained by, for example, (1) reacting a compound of the formula VIII,



in which R^1 , R^4 , R^5 and A are as defined above with a compound of the formula IX,



in which Q is as defined above and Y represents a suitable leaving group, for example, halogen, to give the corresponding compound of formula X,




and then (2) reacting the compound of formula X with an azide. The reaction of step (1) may be carried out in the presence of a base, for example, n-butyl lithium in an inert solvent or mixtures of solvents, for example, hexanes, tetrahydrofuran or hexamethylphosphoramide. The reaction may be carried out at a temperature of, for example, from 0°-50°C. The reaction of step (2) may be carried out in a number of ways as described, for example, in J. March, Advanced Organic Chemistry, Wiley-Interscience, 1985. One method which may be mentioned is achieved by reacting the acid of formula VIII with diphenylphosphoryl azide in the presence of a base, for example, triethylamine, in an inert solvent, for example, toluene at a temperature of, for example, from 20°-120°C.

The starting material for reaction (c) may be obtained from the corresponding compound of formula I in which R² or R³ represent hydrogen by conventional acylation techniques for amines. For example, C₂₋₆ alkanoyl halides or anhydrides may be reacted in the absence of a solvent; however, a suitable inert solvent may be used, for example, toluene, methylene chloride or tetrahydrofuran. The reactions may be carried out in the presence of a base, for example, a tertiary amine such as pyridine. The reactions may be carried out at a temperature of, for example, from 0°-100°C. Another method which may be mentioned is the formation of N-formyl derivatives by reaction of the corresponding amine with the reagent formed by heating formic acid and acetic anhydride at a temperature of, for example, from 0°-75°C. Suitable solvents for the formylation reaction are aprotic solvents, for example, tetrahydrofuran at a temperature of, for example, from 0°-30°C.


The starting material for reaction (f) may be prepared by reaction of the corresponding compound of formula I in which R² and R³ represent hydrogen with the corresponding aldehyde or ketone in the presence of an acid catalyst, for example, p-toluenesulphonic acid, under conditions which promote the elimination of the elements of water, for example, azeotroping with toluene. In some cases the imine is formed *in situ* during the reduction step, in the process known as reductive alkylation, and the reaction may be carried out in the presence of hydrogen and a hydrogenation catalyst, for example, platinum in a protic solvent such as a lower alkanol, for example, ethanol and at a temperature of, for example, from 0°-50°C. In the case where the starting material of

formula V is formed with R^1 and R^2 taken together representing a $C_{3,5}$ alkylidene chain it is prepared by cyclization of the corresponding aldehyde of formula XI,



in which Q, A, R^4 and R^5 are as defined above, R^{1a} represents $-(CH_2)_{2,4}-CHO$ and P represents H or a protecting group removable under the cyclization conditions.

Compounds of formula XI may be prepared by hydrolysis of a corresponding compound of formula XI in which R^{1a} represents a group of the formula,



wherein R^{10} and R^{11} represent $C_{1,3}$ alkyl or taken together represent a $C_{2,3}$ alkylene bridge. Hydrolysis of the acetal may be carried out in aqueous media in the presence of an acid, for example, a mineral acid such as 1N HCl, and at a temperature of, for example, from $0^\circ-50^\circ C$. The starting materials for the acetals of formula XI may be prepared essentially according to the procedures for the preparation of the starting materials of reaction (b) described above or suitable modifications thereof as described in the examples.

The starting material for reaction (i) may be prepared from a corresponding compound of formula I in which R^2 is hydrogen by conventional acylation techniques, for example, by reaction with an activated carboxylic acid derivative which contains a leaving group α - to the carbonyl group, for example, chloroacetyl chloride or bromoacetyl chloride, in the presence of an acid acceptor, for example, triethylamine or pyridine.

The starting materials for reactions (a), (g) and (h) are either well known or may be prepared from known compounds by conventional methods [see for example

'Comprehensive Heterocyclic Chemistry', by Katritzky and Rees, Pergamon Press (1984)].

Pharmaceutically acceptable salts may be formed by reacting the free base, or a salt or derivative thereof with one or more equivalents of the appropriate acid. The reaction may be carried out in a solvent in which the salt is insoluble or in which the salt is soluble or in mixtures of the solvents. Acid addition salts may be converted to the corresponding base, for example, by reacting the salt with sodium hydroxide in water at room temperature. Quaternary salts may be prepared from the corresponding secondary or tertiary amines by conventional methods, for example, as described in J March, Advanced Organic Chemistry, 3rd Ed, Wiley-Interscience, 1985.

Suitable bioprecursor forms of a compound of formula I may be prepared by reacting the corresponding compound of formula I in which one or more of the amino or hydroxyl groups is unprotected with a C₁₋₆ alkanolic acid anhydride, C₁₋₆ alkanoyl halide, C₁₋₆ haloformate ester, or an amino acid or a carboxyl activated derivative thereof. Conventional acylation techniques for amines may be used. The reactions may be carried out in the presence of a base, for example, sodium hydroxide or pyridine. The reactions may be carried out in the absence of a solvent; however, a suitable inert solvent may be used, for example, toluene, methylene chloride or tetrahydrofuran. The reactions may be carried out at a temperature of, for example, from 0°-100°C. The condensation with α -amino acid derivatives may be carried out in conditions similar to those used for the synthesis of peptide bonds in protein chemistry, e.g. by carrying out the reaction in the presence of N,N'-carbonyldiimidazole in a polar aprotic solvent or using a hindered base, e.g. triethylamine and an alkyl chloroformate. When one or both of the amino acid nitrogen substituents is hydrogen, the nitrogen atom requires protection. One particularly suitable protecting group is benzyloxycarbonyl, which may readily be removed by hydrogenolysis or hydrogen bromide in acetic acid. Other groups that may be mentioned include t-butyloxycarbonyl (Boc), which is removed by standing the peptide in cold trifluoroacetic acid; Fmoc, which may be removed by treatment with dilute piperidine (20% in DMF); (4-methoxybenzyl)oxycarbonyl and 2-nitrophenylsulphenyl. Further protecting groups and methods for their removal are

described in T W Greene, Protective Groups in Organic Synthesis, Wiley Interscience, 1981.

Suitable bioprecursor groups which may be mentioned include methoxycarbonyl, ethoxycarbonyl and α -amino acids, for example, glycine, alanine, leucine, proline, methionine, serine and sarcosine. Derivatives of α -amino acids are preferred, especially glycine.

Resolution of compounds with asymmetric centres may be accomplished by methods well known in the art, for example, by separation of their diastereoisomeric salts, chromatography on a chiral column or asymmetric syntheses. Methods of resolution are described in J. March, Advanced Organic Chemistry, 3rd. Edition, Wiley Interscience, 1985.

The compounds of formula I, and their pharmaceutically acceptable derivatives, are useful because they possess pharmacological activity in animals. In particular, the compounds have useful neuroprotective properties. Without being limited by the following explanation, the compounds are thought to possess NMDA blocking properties. Neurodegeneration is known to be caused or accelerated by certain excitatory amino acids found naturally in the central nervous system (CNS). Glutamate is an endogenous amino acid which has been characterized as a fast excitatory transmitter in the mammalian brain. Glutamate is also known as a powerful neurotoxin capable of killing CNS neurons under certain pathologic conditions which accompany stroke and cardiac arrest. It has been shown that the sensitivity of central neurons to hypoxia and ischemia can be reduced by the specific antagonism of post synaptic glutamate receptors. Glutamate is characterized as a broad spectrum agonist having activity at four neuronal excitatory amino acid receptor sites. These receptor sites are named after the amino acids which selectively excite them: kainate (KA), N-methyl-D-aspartate (NMDA), quisqualate (QUIS) and 2-amino-4-phosphonobutyrate (APB). Glutamate is believed to be a mixed agonist capable of binding to and exciting all four receptor types. Thus, agents which selectively block or antagonise the action of glutamate at these receptors can prevent neurotoxic injury associated with anoxia, hypoxia or ischemia. In particular, compounds which bind to the NMDA receptor site

and selectively block the action of glutamate are useful in the prevention and treatment of neurodegenerative diseases.

In addition, the compounds of formula I, and their pharmaceutically acceptable derivatives, demonstrate anticonvulsant activity by their ability to inhibit maximal electroshock (MES) induced seizures in mice, certain compounds inhibit the onset of convulsions and death induced by administration of NMDA to mice and certain compounds demonstrate antihypoxia activity by their ability to increase the survival time of mice in an oxygen depleted environment.

10

Antiepileptic activity may be measured by assessing a compound's ability to prevent the hind limb tonic extension component of the seizure in groups of mice induced by maximal electroshock (MES) after oral or intraperitoneal administration, according to the procedures of the Epilepsy Branch, NINCDS as published by R J Porter *et al*, Cleve Clin Quarterly 1984, 51, 293, and compared with the standard agents dilantin and phenobarbital.

Certain compounds of this invention may possess useful antihypoxia activity. This activity may be conveniently measured in mice. Groups of mice are tested at various times after the intraperitoneal administration of graded doses of the test compound. The animals' survival time in a temperature-controlled hypoxic environment (96% nitrogen and 4% oxygen) is recorded. A statistical comparison is made between coincident vehicle treated animals and the experimental group. The dose-response and minimum active dose (MAD) for compounds are obtained. Other modes of administration can also be used.

NMDA activity may be measured in several ways:

a) NMDA blocking activity is measured by assessing a compound's ability to protect mice from convulsions induced by intravenous administration of 150 mg/kg of NMDA according to the procedures of Czuczwar *et al.*, (Neurotransmitters, Seizures and Epilepsy III, edited by G. Nistico *et al.*, Raven Press, New York 1986, pages 235-246). Groups of mice are pretreated by 30 minutes with the test compound by the oral or intraperitoneal routes and then given NMDA. Animals were observed for convulsions

as defined by loss of righting reflex and appearance of tonic/clonic seizures. Animals are kept for 60 min after NMDA dosing and mortality was recorded.

b) NMDA receptor antagonist activity is measured *in vitro* by assaying a compounds ability to inhibit binding of the receptor antagonist 10,11-dihydro-5-methyl-5H-dibenzo[a,d]-cyclohepten-5,10-imine (MK801) to the receptor. The method is described by Foster and Wong, Br. J. Pharmacol. 91, 403-409 (1987).

c) NMDA and glycine receptor affinity may also be tested in the [³H]L-glutamate and [³H]glycine binding assays following the method of Monaghan & Cotman, PNAS, 83, 7532, (1986) and Watson *et al*, Neurosci Res Comm, 2, 169, (1988).

10

An important factor in judging the usefulness of compounds for the treatment of neurological disorders is an evaluation of their propensity to produce neurotoxic effects. Compounds may be evaluated in acute neurological impairment assays essentially according to the procedures of Coughenour *et al*, Pharmac Biochem Behav, 1977, 6, 351.

15 The therapeutic index for a compound may then be calculated to provide an indication of the relative safety of a compound. Marked side effects of compounds may also be of significance in evaluating the usefulness of compounds. Compounds may be evaluated for their ability to cause significant differences in symptomatology according to the criteria set forth by Irwin, Comprehensive Observational Assessment, Ia. A Systematic, Quantitative Procedure for Assessing the Behavioral and Physiologic State of the Mouse, Psychopharmacologia, 13, 222-257, (1968).

Certain compounds may act as neuromodulators by interfering with neurotransmitter uptake. Undesirable psychotomimetic effects may be associated with a compound's ability to inhibit dopamine uptake. Inhibition of dopamine uptake may be measured according to the method of Holtz *et al*, Molecular Pharmacol, 10, 746 (1974).

Thus, according to another aspect of the invention there is provided a method of treatment of a neurological disorder, which comprises administering to a patient in need of such treatment a therapeutically effective amount of a compound of formula I, as defined above but without proviso (3), or a pharmaceutically acceptable derivative thereof. There is further provided the use of a compound of formula I, as defined above but without proviso (3), or a pharmaceutically acceptable derivative thereof, as

30

active ingredient in the manufacture of a medicament for use in the prevention or treatment of a neurological disorder.

Specific neurological disorders that may be mentioned include stroke, cerebral ischaemia, cerebral palsy, hypoglycaemia, epilepsy, Alzheimer's disease, Huntington's chorea, Olivo-ponto-cerebellar atrophy, perinatal asphyxia, Parkinson's Disease, anoxia and neuronal damage associated with substance abuse, for example, narcotics or cocaine. Stroke is of particular interest.

For the above-mentioned uses the dosage administered will, of course, vary with the compound employed, the mode of administration and the treatment desired. However, in general, satisfactory results are obtained when the compounds are administered at a daily dosage of from about 0.1mg to about 20mg per kg of animal body weight, preferably given in divided doses 1 to 4 times a day or in sustained release form. For man, the total daily dose is in the range of from 5mg to 1,400mg; more preferably from 10mg to 100mg, and unit dosage forms suitable for oral administration comprise from 2mg to 1,400mg of the compound admixed with a solid or liquid pharmaceutical carrier or diluent.

The compounds of formula I, and pharmaceutically acceptable derivatives thereof, may be used in the form of appropriate pharmaceutical formulations. Thus, according to a further aspect of the invention, there is provided a pharmaceutical formulation comprising a compound of formula I, as defined above but without proviso (3), or a pharmaceutically acceptable derivative thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

Examples of such adjuvants, diluents and carriers are:

for tablets and dragees; lactose, starch, talc or stearic acid;

for capsules; tartaric acid or lactose;

for injectable solutions; water, alcohols, glycerin or vegetable oils;

for suppositories: natural or hardened oils or waxes.

Formulations in a form suitable for oral, i.e. oesophageal administration include tablets, capsules and dragees.

Sustained release compositions include those in which the active ingredient is bound to an ion exchange resin which is optionally coated with a diffusion barrier to modify the release properties of the resin.

We prefer such formulations to contain up to 50% and more preferably up to 25% by weight of a compound of formula I, or a pharmaceutically acceptable derivative thereof.

10

The compounds of formula I, and pharmaceutically acceptable derivatives thereof have the advantage that they are less toxic, more efficacious, are longer acting, have a broader range of activity, are more potent, produce fewer side effects, are more easily absorbed or have other more useful pharmacological properties, than prior art compounds in the therapeutic fields mentioned above.

15

The invention is illustrated by the following examples.

Example 1

20 α -Methyl- α -phenyl-2-pyridineethanamine dihydrochloride

a) α -Methyl- α -phenyl-2-pyridinepropanoic acid

A 2.5M hexane solution of butyl lithium (440ml) was added over 1 hour to an ice-cooled solution of phenylacetic acid (70g, 0.51mol), hexamethyl-phosphoramide (91ml) and THF (tetrahydrofuran, 0.8l). The reaction mixture was allowed to warm to room temperature over 1.5 hours, then cooled back to 0°C. A solution of methyl iodide (33ml, 0.52mol) in THF (100ml) was added to the stirred reaction and after 15 minutes at 0°C, then 1.5 hours at room temperature the reaction was cooled back to 0°C and butyl lithium (220ml of a 2.5M hexane solution) was added dropwise. The reaction was stirred at 0°C for 10 minutes and room temperature for 0.5 hour. After cooling to 0°C, a solution of picolyl chloride (0.61mol) in THF (100ml) was added over 0.5 hour. The ice bath was removed and the reaction was stirred overnight at room temperature. The reaction mixture was partitioned between water and ethyl acetate. The basic aqueous

30

layer was neutralized at 0°C with 3N HCl and the precipitated solids were filtered, washed with ether and dried to give the subtitle acid (52g). Extraction of the aqueous filtrate with ethyl acetate and concentration of the ethyl acetate layer afforded a crude residue. The residue was triturated with ether to give an additional 25g of product.

5

b) N-Carbobenzoxy- α -methyl- α -phenyl-2-pyridineethanamine

The acid (57g) from step (a) was dissolved in toluene (1.5l) and triethylamine (36.5ml), then diphenylphosphoryl azide (54.4ml) was added. The mixture was heated to reflux. Reflux was maintained for 3 hours; then the reaction mixture was cooled to 90°C and
10 benzyl alcohol (88.5ml) was added dropwise. Refluxing was resumed and maintained overnight. Concentration of the reaction mixture afforded a dark oil. The oil was subjected to vacuum distillation to remove excess benzyl alcohol and give essentially pure subtitle compound as an oil.

15 c) α -Methyl- α -phenyl-2-pyridineethanamine dihydrochloride

A sample of the N-carbobenzoxy compound (4.8g) prepared in step (b) was hydrogenated in acetic acid (75ml) over 10% palladium-charcoal (900mg) at 3.4atm (50psi) in a Parr apparatus overnight. The catalyst was filtered and the filtrate was concentrated to dryness *in vacuo*. The residue was chromatographed on silica gel and
20 eluted with ammoniated 5-10% CH₃OH/CHCl₃ [1:19-1:9]. The amine fractions were combined to give an oil (2.1g). The amine was converted to the hydrochloride salt by treatment with hydrogen chloride in isopropanol (30ml) followed by addition of ethyl acetate (5ml). The precipitated salt (2.9g) was filtered and dried at 75°C to give the title compound, mp 192-196°C.

25

Alternative preparation of α -methyl- α -phenyl-2-pyridinepropionic acid

A 2.5M hexane solution of butyl lithium (264ml) was added during 1 hour to an ice-cooled solution of α -methylphenylacetic acid (50g, 0.33mol), hexamethyl-phosphoramide (60ml) and THF (0.4l). The reaction mixture was stirred to room temperature for 0.5
30 hour, then cooled back to 0°C. After cooling to 0°C, a solution of picolyl chloride (0.46mol) in THF (100ml) was added over 0.75 hour. The ice bath was removed and the reaction was stirred overnight at room temperature. The reaction mixture was partitioned between water (500ml) and ethyl acetate (500ml). The organic layers were

back extracted with 20% NaOH solution (200ml). The basic aqueous layers were combined and neutralized at 0°C with 3N HCl and the precipitated solids were filtered, washed with ether and dried to give the title acid (63g).

5 **Example 2**

2-Amino-N-[1-methyl-1-phenyl-2-(2-pyridinyl)ethyl] acetamide dihydrochloride

a) **N-(2-chloroacetyl)- α -methyl- α -phenyl-2-pyridineethanamine**

A solution of chloroacetyl chloride (1.7g, 15mmol) in CHCl_3 (10ml) was added to an ice-cooled solution of the title compound of Example 1 (3g, 14.2mmol) and triethylamine
10 (4.2ml) in CHCl_3 (70ml). After 2 hours, the reaction mixture was made basic with 15% NaOH solution. The organic layer was separated, dried (MgSO_4) and concentrated to give a residue which was chromatographed on silica gel and eluted with ethyl acetate/hexane [1:1] to give 2.7g of the subtitle compound.

15

b) **2-Amino-N-[1-methyl-1-phenyl-2-(2-pyridinyl)ethyl] acetamide dihydrochloride**

The product of step (a) was combined with similarly prepared material to give a total of 4.8g which was dissolved in ethanol (125ml) and charged to a Parr bomb and cooled to 0°C. Liquid ammonia (excess) was added and the sealed bomb was heated to 80°C
20 for 24 hours. After cooling the bomb was unsealed and the solution was concentrated to give a residue of 4.5g. The residue was chromatographed on silica gel and eluted with ammoniated $\text{CH}_3\text{OH}/\text{CHCl}_3$ [1:9]. The fractions containing purified product were combined and concentrated to give the desired base (3.2g). The base was converted to the hydrochloride salt by treatment with hydrogen chloride in ethanol/isopropanol
25 solution. The solvents were evaporated and the residue was redissolved in methanol (10ml). Ether was added to the methanol solution and the precipitated solids were isolated to give the title compound (3.6g), mp 254-256°C.

Example 3

30 **Resolution of α -methyl- α -phenyl-2-pyridineethanamine**

A solution of the title compound of Example 1 (34.7g, 0.164mol) in 95% ethanol (170ml) was warmed to 60°C. (-)-Dibenzoyl-L-tartaric acid monohydrate (67.8g, 0.18mol)

was dissolved in 95% ethanol (170ml) at 60°C and added to the amine. The combined solutions were heated to reflux and then cooled to room temperature with stirring. After 3 days the precipitated solids were filtered to give a white solid (28.6g). The solid was recrystallized from 95% ethanol (220ml) to give the dibenzoyl-L-tartaric acid salt (19.5g). A sample of the salt was converted to the hydrochloride salt via the base by conventional methods, $[\alpha]_D = +63.93^\circ$ ($c=0.964$, CH_3OH).

The ethanolic filtrates from the two crystallization steps were concentrated and the residual salts were treated with water (200ml) and concentrated NH_4OH (100ml). The mixture was extracted with methylene chloride and the methylene chloride layer was dried (MgSO_4) and concentrated to give the base (20.5g). The base (20.5g) was treated with (+)-dibenzoyl-D-tartaric acid (40g) in 95% ethanol (300ml) at 60°C. After cooling to room temperature ether (600ml) was added. A solid precipitated and was filtered to give 41.5g of salt. The salt was recrystallized from 95% ethanol to give 27.5g of the enantiomeric salt. A sample of the salt was converted to the dihydrochloride salt, $[\alpha]_D = -58.76^\circ$ ($c=1.045$, CH_3OH).

Example 4

α -(3-Methyl-2-thienyl)-2-pyridineethanamine dimaleate

a) N-(Trimethylsilyl)-3-methyl-2-thiophene carboxaldehyde

The subtitle compound was prepared by adding a 1M solution of lithium bis(trimethylsilylamide) (105ml) dropwise to an ice-cooled solution of 3-methyl-2-thiophene carboxaldehyde (11.7g, 0.93mol) in THF (100ml).

b) α -(3-Methyl-2-thienyl)-2-pyridineethanamine dimaleate

A solution of 2-picoline (9ml) in THF (100ml) was cooled to -78°C and 1.6M butyl lithium in hexane solution (58ml) was added. The solution was stirred to room temperature for 30 minutes, recooled to -78°C and then the solution of the product of step (a) was added dropwise. The reaction mixture was stirred overnight at room temperature. Ether (100ml) was added dropwise followed by 1N HCl (100ml). The aqueous layer was separated, basified with 50% NaOH solution and extracted with ethyl acetate. The ethyl acetate layer was separated, dried (MgSO_4) and concentrated to give

an oil (13.5g). The oil was purified by chromatography on silica gel and eluted with ammoniated $\text{CH}_3\text{OH}/\text{CHCl}_3$ [1:9]. The purified fractions were combined to give an oil. The oil (4.1g) was dissolved in ethanol (40ml) and maleic acid (4.5g) was added. After cooling to 0°C , a solid precipitated which was filtered and dried to give the title compound (5.7g), mp $131\text{--}134^\circ\text{C}$.

Example 5

2-Amino-N-[1-(3-methyl-2-thienyl)-2-(2-pyridinyl)ethyl] acetamide difumarate

By following essentially the same procedure as described in Example 2 above, but substituting α -(3-methyl-2-thienyl)-2-pyridineethanamine (as prepared in Example 4) for α -methyl- α -phenyl-2-pyridineethanamine, the corresponding free base of the title compound was obtained as an oil. The base (1.4g) was then treated with excess fumaric acid in ethanol (40ml). Ether (75ml) and hexane (10ml) were added and a white solid (1.7g) was isolated. The solid was recrystallized from ethanol/ether to give the title compound (1.4g), mp $174\text{--}177^\circ\text{C}$.

Example 6

N-Ethyl- α -(3-methyl-2-thienyl)-2-pyridineethanamine fumarate

20

a) N-Acetyl- α -(3-methyl-2-thienyl)-2-pyridineethanamine

Acetic anhydride (2.1ml) was added to a solution of α -(3-methyl-2-thienyl)-2-pyridineethanamine (from Example 4, 3.1g) in pyridine (20ml). After 3 days the mixture was diluted with water and extracted with ethyl acetate. The ethyl acetate layer was dried (MgSO_4) and concentrated to give the subtitle acetyl derivative.

b) N-Ethyl- α -(3-methyl-2-thienyl)-2-pyridineethanamine fumarate

The product of step (a) (3.1g) was dissolved in THF (30ml) and cooled to 0°C . Borane-THF (1M, 59.4ml) was added and the reaction mixture was stirred overnight. The reaction mixture was decomposed with 20ml of 4N HCl at 0°C . The acidic mixture was basified with 50% NaOH solution at 0°C and the resulting mixture was extracted with ethyl acetate. Concentration of the ethyl acetate layer afforded a residue which was purified by chromatography on silica gel and elution with ethyl acetate/hexane [1:1]

followed by ammoniated $\text{CH}_3\text{OH}/\text{CHCl}_3$ [1:19]. The purified fractions were combined to give the free base of the title compound as an oil (2g). The base was converted to the fumarate salt with fumaric acid (2g) in ethanol (50ml). Ether (100ml) and hexane (5ml) were added and the fumarate salt of the title compound was isolated, mp 153-
5 154°C.

Example 7

N-Allyl- α -phenyl-2-pyridineethanamine dihydrochloride

10 α -Phenyl-2-pyridineethanamine (1.5g), potassium carbonate (1.15g) and allyl bromide (0.74g) were added to acetonitrile (25ml) and the reaction mixture was heated at reflux for 3 hours. The cooled reaction mixture was poured into a mixture of water and ethyl acetate. The ethyl acetate layer was separated, dried (MgSO_4) and concentrated. The residue was chromatographed on silica gel and eluted with $\text{CH}_3\text{OH}/\text{CHCl}_3$ [1:9]. The
15 product-containing fractions were combined and concentrated and the amine obtained was converted to the hydrochloride by treatment with hydrogen chloride in ethyl acetate. The precipitated solids were recrystallized from methanol/ether to give the title compound (0.06g), mp 159-161°C.

20 Example 8

2-Phenyl-2-(2-pyridinylmethyl)piperidine dihydrochloride

a) α -phenyl- α -[3-(1,3-dioxolan-2-yl)propyl]-2-pyridine-propionic acid

A 2.5M hexane solution of butyl lithium (180ml) was added to an ice-cooled solution of
25 phenylacetic acid (20g), hexamethylphosphoramide (25.6ml) and tetrahydrofuran (260ml). The reaction mixture was stirred to room temperature, then cooled back to 0°C. A solution of 2-(3-chloropropyl)-1,3-dioxolane in THF (20ml) was added dropwise and the mixture was stirred to room temperature overnight. The reaction was cooled back down to 0°C then butyl lithium (60ml of a 2.5 M hexane solution) was added
30 dropwise followed by picolyl chloride (0.147mol) in THF (40ml). The ice-bath was removed and the reaction was stirred at room temperature for 3 days. The reaction mixture was quenched with half-saturated aqueous NH_4Cl . Ethyl acetate and chloroform were added to dissolve the solids. The aqueous layer was neutralized with

1N HCl and extracted with chloroform. The combined organic layers were dried (MgSO_4) and concentrated to give a solid which was washed with ether to give the subtitle compound (28.1g).

5 b) N-carbobenzoxy- α -[3-(1,3-dioxolan-2-yl)propyl]- α -phenyl-2-pyridineethanamine

The acid of step (a) (25g), triethylamine (11.2ml) and diphenylphosphoryl azide were dissolved in dry toluene (400ml) and heated at reflux for 3 hours. Benzyl alcohol (30.4ml) was added dropwise and the resulting mixture was refluxed overnight. Concentration of the reaction mixture afforded a dark oil which was purified by
10 chromatography on silica gel and elution with ethyl acetate/hexanes [1:9-1:1] to give the subtitle compound (25g).

c) N-carbobenzoxy- α -phenyl- α -(4-oxobutyl)-2-pyridineethanamine

The amine of step (b) (25g) was dissolved in 1N HCl (300ml) and stirred at room
15 temperature overnight to hydrolyze the acetal group. The solution was neutralized with NaHCO_3 and the amine was extracted into chloroform. Concentration of the chloroform afforded the subtitle compound (27g) as a yellow solid.

d) 2-Phenyl-2-(2-pyridinylmethyl)piperidine dihydrochloride

20 The aldehyde-amine of step (c) (27g) was dissolved in glacial acetic acid (500ml) and 10% Pd-C catalyst (6.0g) was added. The reaction mixture was hydrogenated in a Parr apparatus at 2.7-3.4atm (40-50psi) overnight. The catalyst was filtered and the filtrate was concentrated to dryness. The residue was purified by chromatography on silica gel and elution with $\text{CH}_3\text{OH}:\text{CHCl}_3$ [1:19]. Purified amine product (5.2g) was obtained and
25 converted to the dihydrochloride salt by reaction with hydrogen chloride in isopropanol/ether. The salt was recrystallized from isopropanol/ether to give a solid (1.2g) which was then freeze-dried from an aqueous solution to give the title compound as a hydrate containing 6.4% H_2O , mp 193-196°C.

30 Example 9

α -Phenyl-2-pyridineethanamine 1-oxide

a) 2-(2-Oxo-2-phenylethyl)-pyridine N-oxide

A solution of 2-picoline N-oxide (4.4g, 0.04mol) in benzene (25ml) was added to a suspension of sodium hydride (3.2g of 60% oil dispersion) and methyl benzoate (9.94ml, 0.08mol) in dry benzene (100ml). The reaction mixture was refluxed overnight. Methanol (15ml) was added to the cooled reaction mixture, followed by water (150ml).
5 The aqueous layer was separated and extracted with chloroform (2x40ml). The aqueous layer was acidified with 1N HCl and extracted with chloroform. The combined organic layers were dried (MgSO_4) and concentrated to give the subtitle ketone as a solid (7g), mp 146-148°C.

10 b) α -Phenyl-2-pyridineethanamine 1-oxide

The ketone (10.72g, 0.05mol) prepared in step (a) above was combined with ammonium acetate (38.73g, 0.5mol), sodium cyanoborohydride (2.22g, 0.035mol) and absolute methanol (200ml) and stirred at room temperature for 3 days. The mixture was acidified to pH 1 with concentrated HCl, then the methanol was evaporated. The
15 residue was partitioned between water and chloroform and the aqueous layer was separated and basified with solid KOH. The precipitate was extracted into chloroform and the chloroform layer was dried (MgSO_4). Concentration of the solvent afforded the amine as a syrup (3.3g). The amine was converted to the hydrochloride by dissolving in ethyl acetate and adding a saturated solution of hydrogen chloride in isopropanol until
20 acidic. The precipitated solid was filtered and recrystallized from ethanol/ether to give the title compound as a white solid (2.54g), mp 202-207°C (dec).

Example 10

α -(4-Hydroxyphenyl)-2-pyridineethanamine dihydrochloride

25

a) α -[(4-benzyloxy)phenyl]-2-pyridineethanamine

4-(Benzyloxy)benzaldehyde (5g, 0.023mol) and lithium bis(trimethylsilyl)amide (27ml of a 1M solution in THF, 0.027mol) were mixed and stirred at 0°C for 15 minutes, then for 1 hour at room temperature to form an imine in solution.

30

2-Picoline (2.3ml, 0.023mol) was dissolved in THF (40ml) and cooled to -78°C. n-Butyl lithium (9.2ml of a 2.5M hexane solution) was added and the mixture was stirred to room temperature for 30 minutes then cooled back to -78°C. The imine solution

prepared above was added dropwise and the resulting mixture was stirred to room temperature overnight. Ether was added, then 1N HCl was added until the mixture was acidic, then the reaction was stirred for 30 minutes. The layers were separated and the aqueous layer was cooled to 0°C. Ethyl acetate was added and the mixture was made basic with 50% NaOH solution. The aqueous layer was extracted with ethyl acetate and the separated organic layer was dried (MgSO₄) and concentrated to give a syrup. The syrup was purified by chromatography on silica gel and elution with CH₃OH/CHCl₃ [1:99-1:19] to give the subtitle compound as a pale yellow syrup (4.5g).

10 b) α -(4-Hydroxyphenyl)-2-pyridineethanamine dihydrochloride

The amine of step (a) (2.30g) was dissolved in 95% ethanol (80ml) and hydrogenated over 10% Pd-C (0.50g) at 3.4atm (50psi) in a Parr apparatus overnight. The reaction mixture was mixed with additional 10% Pd-C (0.50g) and hydrogenated for a further 5 hours. The catalyst was filtered and the filtrate was made acidic with saturated hydrogen chloride/ethanol solution. Concentration of the solvent and addition of ether afforded a precipitate on cooling the solution to 0°C overnight. The precipitated solid was isolated and recrystallized from 95% ethanol/ether to give the title compound as the dihydrochloride salt (1.8g), mp 297-305°C (dec).

20 Example 11

α -Phenyl-1-methyl-2-imidazoleethanamine dihydrochloride

A 2.5 M solution of n-butyl lithium in hexane (22ml, 0.055mol) was added dropwise to a solution of 1,2-dimethylimidazole (4.80g, 0.05mol) in THF (200ml) at 0°C. The solution was stirred for 2 hours before it was added to a solution of N-(trimethylsilyl)benzaldimine, prepared by adding 52ml of a 1.0M solution of lithium bis(trimethylsilyl)amide to a solution of benzaldehyde (5.31g, 0.05mol) in THF (25ml) at 0°C and stirring for 30 minutes. The reaction mixture was stirred overnight at room temperature. Water was added and the organic layer was separated. The organic layer was washed with 400ml 1N HCl and the acid layer was basified to pH 10 and then extracted with ether (400ml), followed by methylene chloride (200ml). The organic extracts were combined, dried (MgSO₄) and concentrated to give an oil (7.0g) which was purified by chromatography on silica gel and elution with ammoniated CH₃OH/CHCl₃ [1:19] to give the amine (6.5g). The amine was converted to the dihydrochloride salt

with hydrogen chloride in isopropanol. Ether was added to precipitate the solid salt which was recrystallized from 95% ethanol (60ml) and ether (150ml) to give the title compound as a solid (7.04g), mp 247-9°C (dec).

5 **Example 12**

N-Ethyl- α -methyl- α -phenyl-2-pyridineethanamine dihydrochloride

By following essentially the same procedures as described in Example 6 above and substituting α -methyl- α -phenyl-2-pyridineethanamine (as prepared in Example 1) for α -
10 (3-methyl-2-thienyl)-2-pyridineethanamine the title compound was obtained, mp 200-203°C.

Example 13

N-Isopropyl- α -methyl- α -phenyl-2-pyridineethanamine dimaleate

15

By following essentially the same procedures as described in Example 7 above and substituting α -methyl- α -phenyl-2-pyridineethanamine (as prepared in Example 1) and 2-iodopropane for α -phenyl-2-pyridineethanamine and allyl bromide respectively the free
20 base of the title compound was obtained. The base was converted to the dimaleate salt by treatment with maleic acid (2.1 equivalents) in ethyl acetate/ether and recrystallization from ethyl acetate afforded the title compound, mp 109-111°C.

Example 14

N, α -Dimethyl- α -phenyl-2-pyridineethanamine dihydrochloride

25

a) **N-Formyl- α -methyl- α -phenyl-2-pyridineethanamine**

Formic acid (98%, 1.78ml) was added dropwise to acetic anhydride (3.47ml) at 0°C. The resulting mixture was heated at 55°C for 2 hours then recooled to 0°C and diluted with THF (5ml). A solution of α -methyl- α -phenyl-2-pyridineethanamine (as prepared in
30 Example 1, 3g) in THF (10ml) was added dropwise and the reaction was stirred at 0°C for 30 minutes. The volatiles were removed by vacuum distillation to give the subtitle compound as a syrup (5g).

b) N,α-Dimethyl-α-phenyl-2-pyridineethanamine dihydrochloride

The syrup from step (a) above was dissolved in THF (40ml) and added to 70ml of a 1M BH₃:THF complex at 0°C and the reaction mixture was stirred to room temperature overnight. Hydrochloric acid (45ml, 5M) was added to the ice-cooled reaction mixture and stirring was continued at room temperature overnight. The reaction mixture was basified at 0°C with 15% NaOH solution then extracted with ethyl acetate. The organic layer was separated, dried (MgSO₄) and concentrated to give the methyl amine as a syrup (1.7g). The amine was purified further by chromatography on silica gel and elution with CH₃OH/CHCl₃ [0:1-1:9] to give the base (900mg). The base was converted to the hydrochloride salt by treatment with hydrogen chloride in isopropanol. Ether was added to precipitate the title compound (800mg), mp 190-194°C.

Example 15α-Phenyl-2-(2-pyrazine)ethanamine maleate

15

a) N-(Trimethylsilyl)carboxaldimine

To an ice-cooled solution of benzaldehyde (4.2g, 0.039mol) in THF (150ml) was added dropwise 40ml of a 1M solution of lithium bis(trimethylsilyl)amide in THF. The resulting mixture was stirred at 0°C for 15 minutes, then for 1 hour at room temperature to form the subtitle compound in solution.

20

b) α-Phenyl-2-(2-pyrazine)ethanamine maleate

To the imine solution obtained above at 0°C was added in one portion 2-methylpyrazine (3.7g, 0.039mol) followed by dropwise addition of a 1M solution of lithium bis(trimethylsilyl)amide in THF until the mixture darkened (approximately 3ml). The reaction mixture was stirred overnight at room temperature, cooled to 0°C, diluted with 100ml of ether, and treated with dropwise addition of 1N HCl until pH 1-2 was maintained. The aqueous layer was separated, made basic with 20% NaOH solution, and extracted with chloroform (3x). The chloroform extracts were washed with water, brine, dried and concentrated to give an oil (6.1g). The oil was purified by chromatography on silica gel eluting with ammoniated CH₃OH/CHCl₃ [1:19], taken up in ethanol and treated with maleic acid (1.1 equivalents). The resulting white solid was collected by filtration and dried to give the title compound (2.5g), mp 155-157°C.

30

Example 16 **α -Phenyl-2-(4-pyrimidine)ethanamine maleate**

By following essentially the same procedure as described in Example 15 above and substituting 4-methylpyrimidine for 2-methylpyrazine the title compound was obtained as a white solid (1.6g), mp 133-136°C.

Example 17 **α -Phenyl-2-(3-pyridazine)ethanamine maleate**

10

By following essentially the same procedure as described in Example 15 above and substituting 3-methylpyridazine for 2-methylpyrazine the title compound was obtained as a white solid (2.2g), mp 142-144°C.

Example 18 **α -Phenyl-2-[2-(3-methoxy)pyrazine]ethanamine maleate**

By following essentially the same procedure as described in Example 15 above and substituting 2-methoxy-3-methylpyrazine for 2-methylpyrazine the title compound was obtained as a white solid (1.4g), mp 113-116°C.

20

Example 19 **α -Phenyl-2-[2-(3-chloro)pyrazine]ethanamine hydrochloride**

By following essentially the same procedure as described in Example 15 above and substituting 2-chloro-3-methylpyrazine for 2-methylpyrazine, the free base of the title compound was obtained as an oil. The base (2.7g) was treated with an excess of isopropanol/HCl in isopropanol. The tan solid was collected by filtration and recrystallized from isopropanol/ethyl acetate to give the title compound as an off-white solid (1.7g), mp 196-198°C.

30

Example 20 **α -(2-furanyl)-2-pyridineethanamine dihydrochloride**

By following essentially the same procedure as described in Example 4 above and substituting 2-furaldehyde for 3-methyl-2-thiophene carboxaldehyde the free base of the title compound was obtained as an oil. The base (4.0g) was treated with excess isopropanol/HCl in isopropanol. The off-white solid was collected by filtration and dried to give the title compound (4.5g), mp 215-220°C.

Example 21

α -Phenyl-2-[2-(6-chloro)pyridine]ethanamine hydrochloride

By following essentially the same procedure as described in Example 4 above and substituting benzaldehyde and 6-chloro-2-picoline for 3-methyl-2-thiophene carboxaldehyde and 2-picoline respectively the free base of the title compound was obtained as an oil. The base (5.2g) was treated with an excess of ethanol/HCl in ethanol. The white solid was collected by filtration and dried to give the title compound (1.3g), mp 209-212°C.

Example 22

N-Ethyl-1-phenyl-2-(3-pyridazine)ethanamine hydrochloride

To a Parr bottle charged with platinum oxide (120mg) was added a solution of α -phenyl-2-(3-pyridazine)ethanamine (as prepared in Example 17, 4.1g, 0.02mol) in 120ml of ethanol followed by 1.73ml (0.031mol) of acetaldehyde under nitrogen. The mixture was subjected to hydrogenation at 2.7atm (40psi) of hydrogen for 15 minutes, filtered through celite, and the filtrate concentrated to give a dark oil (5.2g). The oil was purified by chromatography on silica gel eluting with ammoniated CH₃OH/CHCl₃ [1:19-1:9] gradient, dissolved in absolute ethanol (20ml), and made acidic by adding ethanol/HCl. The resulting off-white solid was collected by filtration and dried to give the title compound (1.1g), mp 163-164°C.

Example 23

N-Ethyl-1-phenyl-2-(4-pyrimidine)ethanamine hydrochloride

By following essentially the same procedure as described in Example 22 above and substituting α -phenyl-2-(4-pyrimidine)ethanamine for α -phenyl-2-(3-pyridazine)ethanamine (as prepared in Example 16), the title compound was obtained as a white solid (1.4g), mp 161-162°C.

5

Example 24

N-Ethyl-1-phenyl-2-(2-pyrazine)ethanamine hydrochloride

By following essentially the same procedure as described in Example 22 above and substituting α -phenyl-2-(2-pyrazine)ethanamine (as prepared in Example 15) for α -phenyl-2-(3-pyridazine)ethanamine, the title compound was obtained as a white solid (1.2g), mp 205-206°C.

Example 25

N-Isopropyl-1-phenyl-2-(2-pyrazine)ethanamine fumarate

By following essentially the same procedure as described in Example 22 above and substituting α -phenyl-2-(2-pyrazine)ethanamine (as prepared in Example 15) and acetone for α -phenyl-2-(3-pyridazine)ethanamine and acetaldehyde respectively, and treating the purified free base with fumaric acid (1.2 equivalents) in ethanol/ethyl acetate the title compound was obtained as a white solid (2.3g), mp 169-170°C.

Example 26

N-Methyl-1-phenyl-2-(2-pyrazine)ethanamine dihydrochloride

25

To a stirred mixture of α -phenyl-2-(2-pyrazine)ethanamine (as prepared in Example 15, 3.9g, 0.02mol), and NaOH (1.0g, 0.024mol) in a solvent mixture of 2ml of water and 8ml of t-butanol was added dropwise a solution of t-butyloxycarbonyl anhydride (5.9g, 0.027mol) in 2ml of water and 7ml of t-butanol. The reaction mixture was stirred at room temperature for 15 minutes, during which time a white solid had precipitated. An additional 8ml of t-butanol was added, the mixture cooled to 0°C and 1N sulphuric acid was added until pH 1-2 was obtained. The mixture was extracted with chloroform (3x), the organics combined, washed with brine, and dried. The resulting crude off-white solid

30

(6.4g) was slurried with ether, collected by filtration and dried to give purified product as a white solid (5.0g).

To an ice-cooled solution of the white solid (3.g, 0.01mol) and iodomethane (1ml, 0.016mol) in 50ml of THF was added in portions sodium hydride (0.64g, 0.016mol, 60% dispersion in oil). The resulting mixture was allowed to warm to room temperature, stirred for 2 days, and partitioned between water and chloroform. The aqueous layer was extracted with CHCl_3 (2x), the organics combined, washed with water, brine, and dried. The resulting dark oil (4.5g) was purified by chromatography on silica gel eluting with ammoniated 0-3% $\text{CH}_3\text{OH}/\text{CHCl}_3$ to give purified product as a yellow oil (2.5g).

To a solution of the oil (1.9g, 6mmol) in 20ml of CH_3OH was added 1.3ml of concentrated aqueous HCl, and the resulting mixture heated at reflux temperature for 1 hour. The mixture was concentrated to dryness to give a dark oil (2.4g) which on standing in a solvent mixture of ethanol and ethyl acetate gave a pale yellow solid (1.3g). Recrystallization of the solid from hot ethanol gave the title compound as an off-white solid (1.0g), mp 157-159°C.

Example 27

α -Phenyl-2-[2-(6-hydroxymethyl)pyridine]ethanamine hydrochloride

a) α -Phenyl-2-[2-(6-methyl)pyridine N-oxide]ethanamine

By following essentially the same procedure as described in Example 15 above and substituting 2,6-lutidine N-oxide (2.5 equivalents) for 2-methylpyrazine the subtitle compound was obtained as a syrup after chromatography on silica gel.

b) N-trifluoroacetyl- α -Phenyl-2-[2-(6-hydroxymethyl)pyridine]ethanamine

To an ice-cooled solution of the product of step (a) (5.3g, 0.023mol) in DMF (dimethylformamide, 50ml) was added dropwise with stirring 40ml of trifluoroacetic anhydride (0.28mol). The resulting mixture was allowed to warm to room temperature and stir for 2 days. The residue obtained after concentrating to near dryness was partitioned between ether and water, the aqueous layer separated and extracted with ether (3x). The organic extracts were combined, dried, and the resulting crude dark oil

was purified by chromatography on silica gel to give the subtitle compound as an oil (3.6g).

c) α -Phenyl-2-[2-(6-hydroxymethyl)pyridine]ethanamine hydrochloride

5 To a solution of the product of step (b) (2.6g) in 50ml of methanol was added 30ml of 25% sodium hydroxide solution. The resulting mixture was heated at reflux temperature for 2 hours, cooled, concentrated to a small volume, and partitioned between ethyl acetate and water. The aqueous layer was separated and extracted with ethyl acetate (3x), the organic layers combined and dried. The resulting crude product was purified
10 by chromatography on silica gel, dissolved in a solvent mixture of isopropanol and ether and treated with fumaric acid (1.1 equivalents). The white solid was collected by filtration and freeze dried from water (125ml) to give the title compound as a white solid (0.7g), mp 60°C (softens).

15 Example 28

6-[(2-Amino-2-phenyl)ethyl]-2-picolinamide dihydrochloride

a) α -Phenyl-2-(2-pyridine N-oxide)ethanamine

By following essentially the same procedure as described in Example 15 above and
20 substituting picoline N-oxide for 2-methylpyrazine, the subtitle compound was obtained as a syrup after chromatography on silica gel.

b) N-Trifluoroacetyl- α -phenyl-2-(2-pyridine N-oxide)ethanamine

To an ice-cooled mixture of the product of step (a) (87.8g, 0.4mol) and sodium
25 carbonate (123g) in a solvent mixture of ether (2l) and THF (1l) was added dropwise trifluoroacetic anhydride (114ml, 0.8mol). The resulting mixture was allowed to warm to room temperature and stirred overnight. The mixture was then partitioned between ethyl acetate and water, the aqueous layer extracted with ethyl acetate (3x), the organic layers combined, dried and concentrated to give crude subtitle compound as a brown
30 semi-solid (80.9g).

c) N-Trifluoroacetyl- α -phenyl-2-[2-(6-cyano)pyridine]ethanamine

To the product of step (b) was added dropwise dimethylsulphate (24.7ml, 0.26mol) and the resulting slurry heated at 100°C for 2 hours. The cooled reaction mixture was taken up in 2l of water and added gradually to sodium cyanide (38.1g, 0.78mol) in a stirred solvent mixture of water and ethyl acetate. The dark solution was stirred for 2 hours, the organic layer separated, dried and concentrated to give crude subtitle compound as a dark solid (76.8g). Chromatography on silica gel followed by recrystallization from ethyl acetate/hexanes gave purified title compound as a tan solid (16.6g).

d) 6-[(2-trifluoroacetamido-2-phenyl)ethyl]-2-picolinamide

A solution of the product of step (c) (3.82g, 0.012mol) in 120ml of acetone was added to a mixture of 120ml of 15% hydrogen peroxide solution and 24ml of 1N sodium hydroxide. The resulting mixture was heated at 55°C for 2 hours, concentrated to near dryness and the residue partitioned between water and ethyl acetate. The organic layer was separated, dried and concentrated to give crude subtitle compound as a yellow solid (5.6g). The solid was subjected to chromatography on silica gel to give the subtitle compound as an off-white solid (3.4g).

e) 6-[(2-Amino-2-phenyl)ethyl]-2-picolinamide dihydrochloride

A mixture of the product of step (b), potassium carbonate (7g), water (25ml), and methanol (100ml) was heated at reflux temperature for 2 hours. After cooling, the mixture was concentrated to near dryness and the residue triturated with CH₃OH/CHCl₃ [1:5] to afford a crude solid product. Purification by chromatography on silica gel gave an off-white solid which was dissolved in ethanol/ether and made acidic by adding ethanol/HCl. The white solid was collected by filtration and freeze dried from water to give the title compound (1.25g), mp 146-149°C.

Example 29

α-Phenyl-2-[2-(6-amino)pyridine]ethanamine dihydrochloride

To an ice-cooled stirred solution of KOH (1.1g, 0.019mol) in 90ml of methanol was added in one portion of 6-[(2-trifluoroacetamido-2-phenyl)ethyl]-2-picolinamide [as prepared in Example 28(a), 3.27g, 9.7mmol]. When dissolution was complete iodobenzene diacetate (3.12g, 0.019mol) was added in one portion and the resulting

mixture stirred at 0°C for 30 minutes and then at room temperature for 1 hour. The volatiles were evaporated and the residue partitioned between water and chloroform. The organic layer was separated, dried and concentrated to give an off-white solid which was recrystallized from ethyl acetate/hexanes to give a white solid (2.95g).

5

A solution of the white solid in 250ml of concentrated aqueous hydrochloric acid was heated at reflux temperature for 20 hours, then concentrated to near dryness to give a yellow semi-solid residue. Recrystallization from ethanol/H₂O/ethyl acetate followed by freeze drying from water gave the title compound as an off-white solid (1.56g), mp 265-10 272°C.

Example 30

α -Phenyl-2-[2-(6-amidino)pyridine]ethanamine dihydrochloride

15 a) 6-cyano-2-(2-oxo-2-phenylethyl)-pyridine

To a solution of 2-cyano-6-methylpyridine (9.7g, 0.082mol) in 400ml of dry THF at -78°C was added dropwise 90ml of a 1M solution of lithium bis(trimethylsilyl)amide in THF. After stirring for 30 minutes a solution of methyl benzoate (30ml, 0.245mol) in 50ml of THF was added dropwise. The resulting mixture was allowed to warm to room 20 temperature and stirred overnight. The mixture was cooled to 0°C, quenched with 1N HCl, made basic with 15% NaOH solution, and extracted with ethyl acetate (3x). The organic layer was separated, dried, and concentrated to give crude material which was purified by chromatography on silica gel to give 2.5g of the subtitle compound.

25 b) α -Phenyl-2-[2-(6-amidino)pyridine]ethanamine dihydrochloride

A mixture of the ketone obtained above, hydroxylamine hydrochloride (1.56g), and sodium acetate (1.85g) in 50ml of 50% aqueous ethanol was heated at 50°C for 12 hours. The mixture was evaporated to half volume, extracted with ethyl acetate (3x), and the organic extracts combined and dried. The resulting crude product was purified 30 by chromatography on silica gel to give 2.4g of white solid.

A solution of the white solid and 10% Pd-C catalyst (1g) in 60ml of glacial acetic acid was subjected to 2.7atm (40psi) of hydrogen on a Parr apparatus for 2 days. The


reaction mixture was filtered through celite, the filtrate concentrated to dryness and the resulting crude product purified by chromatography on silica gel to give an oil (2.7g). The oil was dissolved in isopropanol, made acidic with isopropanol/HCl and the resulting solid recrystallized from ethanol/ether and freeze-dried from water to give the title compound as a white solid (1.7g), mp 175-185°C.

Example 31

The title compound of Example 1 was tested for anticonvulsant activity against MES induced convulsions and found to have an ED₅₀ (po) of 10.4mg/kg.

Claims:

1. A compound of formula I,



wherein

A represents C=C, S or O;

Q represents a 5- or 6-membered unsaturated heterocyclic ring having a nitrogen atom in the position adjacent to the point of attachment, 0-3 further heteroatoms selected from N, O and S, and substituents R⁶ and R⁷;

R¹ represents H or C₁₋₆ alkyl;

R² represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl, C₃₋₆ cycloalkyl or NH₂CH₂CO-;

in addition, R¹ and R² taken together may form a C₃₋₅ alkylene chain;

R³ represents H, C₁₋₆ alkyl, C₃₋₆ alkenyl, C₃₋₆ alkynyl;

R⁴ and R⁵ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl or NR⁸R⁹;

R⁶ and R⁷ independently represent H, OH, C₁₋₆ alkoxy, C₁₋₆ alkyl, halogen, trifluoromethyl, C₁₋₆ hydroxyalkyl, amidino, CONH₂ or NR⁸R⁹;

in addition, R⁶ and R⁷ may independently represent O when substituted on N;

R⁸ and R⁹ independently represent H or C₁₋₆ alkyl;

provided that:

- (1) when A represents C=C; R², R³, R⁴ and R⁵ each represent H; and Q represents 2-pyridinyl, 5- or 6-methyl-2-pyridinyl or 5-ethyl-2-pyridinyl; then R¹ is other than H;
 - (2) when A represents C=C; R² represents t-butyl or NH₂CH₂CO-; R³, R⁴ and R⁵ each represent H; and Q represents 2-pyridinyl; then R¹ is other than H;
 - (3) when A represents S or O; R² and R³ represent H; and Q represents 2-pyridinyl; then, either R¹ or one of R⁴ and R⁵ is other than H;
- and pharmaceutically acceptable derivatives thereof.

2. A compound as claimed in claim 1, wherein A represents C=C.
3. A compound as claimed in claim 1 or claim 2, wherein Q represents 2-pyridinyl.
4. A compound as claimed in claim 1 or claim 2, wherein Q represents 2-pyrazinyl.
5. A compound as claimed in any one of the preceding claims, wherein R¹ represents C₁₋₆ alkyl.
6. A compound as claimed in any one of the preceding claims, wherein R⁴, R⁵, R⁶ and R⁷ each represent H.
7. A compound as claimed in claim 1, which is
 - α -Methyl- α -phenyl-2-pyridineethanamine,
 - 10 2-Amino-N-[1-methyl-1-phenyl-2-(2-pyridinyl)ethyl]acetamide,
 - (-)- α -Methyl- α -phenyl-2-pyridineethanamine,
 - (+)- α -Methyl- α -phenyl-2-pyridineethanamine,
 - α -(3-Methyl-2-thienyl)-2-pyridineethanamine,
 - 2-Amino-N-[1-(3-methyl-2-thienyl)-2-(2-pyridinyl)ethyl]acetamide,
 - 15 N-Ethyl- α -(3-methyl-2-thienyl)-2-pyridineethanamine,
 - N-Allyl- α -phenyl-2-pyridineethanamine,
 - 2-Phenyl-2-(2-pyridinylmethyl)piperidine,
 - α -Phenyl-2-pyridineethanamine 1-oxide,
 - α -(4-Hydroxyphenyl)-2-pyridineethanamine,
 - 20 α -Phenyl-1-methyl-2-imidazoleethanamine,
 - N-Ethyl- α -methyl- α -phenyl-2-pyridineethanamine,
 - N-Isopropyl- α -methyl- α -phenyl-2-pyridineethanamine,
 - N, α -Dimethyl- α -phenyl-2-pyridineethanamine,
 - α -Phenyl-2-(2-pyrazine)ethanamine,
 - 25 α -Phenyl-2-(4-pyrimidine)ethanamine,
 - α -Phenyl-2-(3-pyridazine)ethanamine,
 - α -Phenyl-2-[2-(3-methoxy)pyrazine]ethanamine,
 - α -Phenyl-2-[2-(3-chloro)pyrazine]ethanamine,
 - α -(2-furanyl)-2-pyridineethanamine,
 - 30 α -Phenyl-2-[2-(6-chloro)pyridine]ethanamine,
 - N-Ethyl-1-phenyl-2-(3-pyridazine)ethanamine,
 - N-Ethyl-1-phenyl-2-(4-pyrimidine)ethanamine,
 - N-Ethyl-1-phenyl-2-(2-pyrazine)ethanamine,

N-Isopropyl-1-phenyl-2-(2-pyrazine)ethanamine,
 N-Methyl-1-phenyl-2-(2-pyrazine)ethanamine,
 α -Phenyl-2-[2-(6-hydroxymethyl)pyridine]ethanamine,
 6-[(2-Amino-2-phenyl)ethyl]-2-picolinamide,
 5 α -Phenyl-2-[2-(6-amino)pyridine]ethanamine,
 α -Phenyl-2-[2-(6-amidino)pyridine]ethanamine,
 or a pharmaceutically acceptable derivative thereof.

8. A method of treatment of a neurological disorder, which comprises administering to a patient in need of such treatment a therapeutically effective amount
 10 of a compound of formula I, as defined in claim 1 but without proviso (3), or a pharmaceutically acceptable derivative thereof.

9. The use of a compound of formula I, as defined in claim 1 but without proviso (3), or a pharmaceutically acceptable derivative thereof, as active ingredient in the manufacture of a medicament for use in the prevention or treatment of a neurological
 15 disorder.

10. A pharmaceutical formulation comprising a compound of formula I, as defined in claim 1, but without proviso (3), or a pharmaceutically acceptable derivative thereof, in association with a pharmaceutically acceptable adjuvant, diluent or carrier.

11. A process for the preparation of a compound of formula I, as defined in claim
 20 1, or a pharmaceutically acceptable derivative thereof, which comprises:


(a) preparing a compound of formula I in which R^1 , R^2 and R^3 each represent hydrogen, by reacting a corresponding compound of formula II,



II

25


wherein Q is as defined in claim 1, with a compound of formula III,



30


wherein R^4 , R^5 and A are as defined in claim 1, in the presence of a base;

(b) preparing a compound of formula I in which R^2 and R^3 represent hydrogen, by reacting the corresponding azide of formula IV,



in which Q, R^1 , R^4 , R^5 and A are as defined in claim 1, under Curtius reaction conditions;

(c) preparing a compound of formula I in which R^2 represents H and R^3 represents C_{1-6} alkyl, by reduction of a corresponding compound of formula IVa,




wherein R^{3a} represents C_{1-6} alkanoyl and Q, R^1 , R^4 and R^5 are as defined in claim 1;

(d) preparing a compound of formula I in which one or both of R^2 and R^3 represents methyl, by reacting the corresponding compound of formula I in which one or both of R^2 and R^3 is hydrogen with formaldehyde and formic acid;

(e) preparing a compound of formula I in which R^2 or R^3 represents C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl by reacting the corresponding compound of formula I in which R^2 or R^3 represents hydrogen with an alkylating agent of the formula R^{10} -M, in which R^{10} represents a C_{1-6} alkyl, C_{3-6} alkenyl or C_{3-6} alkynyl group and M represents a suitable leaving group;

(f) preparing a compound of formula I in which R^1 represents H or C_{1-6} alkyl, R^2 represents C_{2-6} alkyl or C_{3-6} cycloalkyl, R^3 represents H and, in addition, R^1 and R^2 taken together may form a $C_{3,5}$ alkylene chain, by reduction of the corresponding imine of formula V,

40




5

wherein Q, R¹, R⁴, R⁵ and A are as defined in claim 1, R² represents C₂₋₆ alkylidene or C₃₋₆ cycloalkylidene, and, in addition, R¹ and R² taken together may form a C₃₋₅ alkylidene chain;

10

(g) preparing a compound of formula I in which R¹, R² and R³ represent hydrogen, by reductive amination of the corresponding ketone of formula VI,




15

wherein Q, A, R⁴ and R⁵ are as defined in claim 1;

20

(h) preparing a compound of formula I in which R¹, R² and R³ represent hydrogen, by reduction of a corresponding compound of formula VII,




25

wherein Q, A, R⁴ and R⁵ are as defined in claim 1;

30

(i) preparing a compound of formula I in which R² represents -OCCH₂NH₂, by reacting a corresponding compound of formula VIIa,

41



wherein L is a suitable leaving group and Q, A, R¹, R³, R⁴ and R⁵ are as defined in claim 1, with ammonia; or

- (j) preparing a compound of formula I by removal of a protecting group from an amino- or hydroxy-protected analogue of a compound of formula I;
 and where desired or necessary converting the resulting compound of formula I into a pharmaceutically acceptable derivative thereof or vice versa.

INTERNATIONAL SEARCH REPORT

PCT/GB 92/01971

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl. 5	C07D213/38; C07D401/06;	C07D213/40; C07D233/54;
	C07D409/06; C07D241/12;	C07D405/06 C07D241/16
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
Int.Cl. 5	C07D ; A61K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
X	DE,A,2 447 258 (BAYER AG) 8 April 1976 cited in the application *compound CXXXIV*	1-3
A	*compound CXXXV, CXXXVI, CXXV, CXXVI* see claims ---	1,11
X,P	TETRAHEDRON LETTERS vol. 33, no. 26, 23 June 1992, OXFORD GB pages 3801 - 3804 S. FUSTERO ET AL. 'Synthesis and reactivity of beta-amino-alpha,beta- unsaturated oxa- and thiazolines.' *compound 4* see page 3803 --- -/--	1,2
¹⁰ Special categories of cited documents : "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "&" document member of the same patent family		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search 21 JANUARY 1993		Date of Mailing of this International Search Report 18.02.93
International Searching Authority EUROPEAN PATENT OFFICE		Signature of Authorized Officer P. BOSMA

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category °	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
A	EP,A,0 278 090 (PENNWALT CORPORATION) 17 August 1988 *illustration 4* see claim 9; example 8 & US,A,4 769 466 cited in the application ---	1
A	SYNTHESIS. no. 12, September 1985, STUTTGART DE pages 1138 - 1140 I.A. CLIFFE ET AL. 'Sterically hindered lithium dialkylamides; a novel synthesis of lithium dialkylamides from N-t-alkyl-N-benzylideneamines and the isolation of highly hindered s-alkyl-t-alkylamines.' cited in the application *compound 3h* see page 1140 ---	1,11
A	EP,A,0 346 791 (G.D. SEARLE & CO.) 20 December 1989 cited in the application see the whole document ---	1,9,10, 11
A	EP,A,0 356 035 (FISONS CORPORATION) 28 February 1990 cited in the application see the whole document ---	1,9,10, 11
A	EP,A,0 446 097 (JOUVEINAL S.A.) 11 September 1991 see claims 1-10; examples 1-22 -----	1-13

INTERNATIONAL SEARCH REPORT

International application No.

PCT/GB92/01971

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Remark: Although claim 8 is directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

ANNEX TO THE INTERNATIONAL SEARCH REPORT ON INTERNATIONAL PATENT APPLICATION NO.

GB 9201971
SA 65930

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 21/01/93

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
DE-A-2447258	08-04-76	FR-A- 2265373	24-10-75
		JP-A- 50129721	14-10-75
		NL-A- 7503743	30-09-75
		SE-A- 7503550	29-09-75
EP-A-0278090	17-08-88	US-A- 4769466	06-09-88
		CA-A- 1299571	28-04-92
		JP-A- 63201169	19-08-88
EP-A-0346791	20-12-89	JP-A- 2036171	06-02-90
EP-A-0356035	28-02-90	DK-A- 8903941	13-02-90
		WO-A- 9111995	22-08-91
		JP-A- 2131452	21-05-90
EP-A-0446097	11-09-91	FR-A- 2658817	30-08-91
		US-A- 5017723	21-05-91